Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.45 |
| ▸ | TP53 | P04637 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.45 |
| ▸ | RELA | Q04206 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.42 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 4/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16069650 | 0.92 | HPGD (0.48) | HPGDHSD17B10TP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL16074988 | 0.90 | MAPT (0.42) | HPGDHSD17B10TP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL16069633 | 0.85 | NPC1 (0.46) | HPGDHSD17B10TP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL16075009 | 0.84 | MAPT (0.47) | HPGDHSD17B10SMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL16069530 | 0.82 | MAPT (0.42) | HPGDHSD17B10TP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL17523137 | 0.81 | APP (0.48) | HPGDHSD17B10TP53ALDH1A1KDM4E | |
| SCHEMBL16069668 | 0.78 | APP (0.37) | ALOX5NPC1RAB9AMAPTPOLB | |
| SCHEMBL16069651 | 0.78 | KMT2A (0.38) | HPGDHSD17B10TP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL16069639 | 0.77 | AGPAT2 (0.41) | HPGDHSD17B10TP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL17523119 | 0.76 | MAPT (0.46) | HPGDHSD17B10TP53SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9670170-B2 | Resorufin derivatives for treatment of oxidative stress disorders | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2017-06-06 | — | — | US | disclosed |
| US-9296712-B2 | Resorufin derivatives for treatment of oxidative stress disorders | EDISON PHARMACEUTICALS, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20160039775-A1 | RESORUFIN DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | PTC THERAPEUTICS, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20140275054-A1 | RESORUFIN DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | EDISON PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039775-A1 | RESORUFIN DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | TXNRD2, NDUFAB1, NDUFAF1 | HPGD 180/4885HSD17B10 278/4885TP53 2557/4885 |
| US-20140275054-A1 | RESORUFIN DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | TXNRD2, NDUFAB1, NDUFAF1 | HPGD 180/4885HSD17B10 278/4885TP53 2557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.